CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.

Serap Bilge, Barış Ekici
{"title":"CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.","authors":"Serap Bilge,&nbsp;Barış Ekici","doi":"10.1186/s42238-021-00108-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Autism spectrum disorder is a neurodevelopmental disorder characterized by deficits in communication, social interaction, restricted interest, and repetitive behaviors. Although more cases are being diagnosed, no drugs are approved to treat the core symptoms or cognitive and behavioral problems associated with autism. Therefore, there is an urgent need to develop an effective and safe treatment.</p><p><strong>Objective: </strong>In this study, we aim to share our 2-year experience with CBD-enriched cannabis treatment in autism and review the latest studies.</p><p><strong>Materials and methods: </strong>The study included 33 (27 males, six females) children diagnosed with autism spectrum disorder who were followed up between January 2018 and August 2020. The mean age was 7.7 ± 5.5 years. The average daily dosage of cannabidiol (CBD) was 0.7 mg/kg/day (0.3-2 mg/kg/day). The median duration of treatment was 6.5 months (3-28 months). The preparations used in this study contained full-spectrum CBD and trace elements tetrahydrocannabinol (THC) of less than 3%.</p><p><strong>Results: </strong>The outcomes were evaluated before and after treatment based on clinical interviews. At each follow-up visit, parents were asked to evaluate the effectiveness of the CBD-enriched cannabis treatment. According to the parents' reports, no change in daily life activity was reported in 6 (19.35%) patients. The main improvements of the treatment were as follows: a decrease in behavioral problems was reported in 10 patients (32.2%), an increase in expressive language was reported in 7 patients (22.5%), improved cognition was reported in 4 patients (12,9%), an increase in social interaction was reported in 3 patients (9.6%), and a decrease in stereotypes was reported in 1 patient (3.2%). The parents reported improvement in cognition among patients who adhered to CBD-enriched cannabis treatment for over two years. The antipsychotic drug could be stopped only in one patient who showed mild ASD symptoms. No change could be made in other drug use and doses. Additionally, this study includes an extensive review of the literature regarding CBD treatment in autism spectrum disorder. According to recent studies, the average dose of CBD was 3.8±2.6 mg/kg/day. The ratio of CBD to THC in the used preparations was 20:1. The most significant improvements were seen in the behavioral problems reported in 20-70% of the patients.</p><p><strong>Conclusion: </strong>Using lower doses of CBD and trace THC seems to be promising in managing behavioral problems associated with autism. In addition, this treatment could be effective in managing the core symptoms and cognitive functions. No significant side effects were seen at the low doses of CBD-enriched cannabis when compared to other studies.</p>","PeriodicalId":15172,"journal":{"name":"Journal of Cannabis Research","volume":" ","pages":"53"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675523/pdf/","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cannabis Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42238-021-00108-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

Introduction: Autism spectrum disorder is a neurodevelopmental disorder characterized by deficits in communication, social interaction, restricted interest, and repetitive behaviors. Although more cases are being diagnosed, no drugs are approved to treat the core symptoms or cognitive and behavioral problems associated with autism. Therefore, there is an urgent need to develop an effective and safe treatment.

Objective: In this study, we aim to share our 2-year experience with CBD-enriched cannabis treatment in autism and review the latest studies.

Materials and methods: The study included 33 (27 males, six females) children diagnosed with autism spectrum disorder who were followed up between January 2018 and August 2020. The mean age was 7.7 ± 5.5 years. The average daily dosage of cannabidiol (CBD) was 0.7 mg/kg/day (0.3-2 mg/kg/day). The median duration of treatment was 6.5 months (3-28 months). The preparations used in this study contained full-spectrum CBD and trace elements tetrahydrocannabinol (THC) of less than 3%.

Results: The outcomes were evaluated before and after treatment based on clinical interviews. At each follow-up visit, parents were asked to evaluate the effectiveness of the CBD-enriched cannabis treatment. According to the parents' reports, no change in daily life activity was reported in 6 (19.35%) patients. The main improvements of the treatment were as follows: a decrease in behavioral problems was reported in 10 patients (32.2%), an increase in expressive language was reported in 7 patients (22.5%), improved cognition was reported in 4 patients (12,9%), an increase in social interaction was reported in 3 patients (9.6%), and a decrease in stereotypes was reported in 1 patient (3.2%). The parents reported improvement in cognition among patients who adhered to CBD-enriched cannabis treatment for over two years. The antipsychotic drug could be stopped only in one patient who showed mild ASD symptoms. No change could be made in other drug use and doses. Additionally, this study includes an extensive review of the literature regarding CBD treatment in autism spectrum disorder. According to recent studies, the average dose of CBD was 3.8±2.6 mg/kg/day. The ratio of CBD to THC in the used preparations was 20:1. The most significant improvements were seen in the behavioral problems reported in 20-70% of the patients.

Conclusion: Using lower doses of CBD and trace THC seems to be promising in managing behavioral problems associated with autism. In addition, this treatment could be effective in managing the core symptoms and cognitive functions. No significant side effects were seen at the low doses of CBD-enriched cannabis when compared to other studies.

Abstract Image

富含cbd的大麻治疗自闭症谱系障碍:土耳其单一中心的经验和文献综述。
简介:自闭症谱系障碍是一种神经发育障碍,其特征是沟通缺陷、社会互动、兴趣限制和重复行为。虽然越来越多的病例被诊断出来,但没有药物被批准用于治疗与自闭症相关的核心症状或认知和行为问题。因此,迫切需要开发一种有效和安全的治疗方法。目的:在本研究中,我们旨在分享我们两年来在cbd丰富的大麻治疗自闭症方面的经验,并回顾最新研究。材料与方法:该研究包括33名被诊断为自闭症谱系障碍的儿童(27名男性,6名女性),他们在2018年1月至2020年8月期间接受了随访。平均年龄7.7±5.5岁。大麻二酚(CBD)的平均日剂量为0.7 mg/kg/day (0.3-2 mg/kg/day)。治疗中位持续时间为6.5个月(3-28个月)。本研究使用的制剂中含有全谱CBD和微量元素四氢大麻酚(THC),含量小于3%。结果:通过临床访谈对治疗前后的疗效进行评价。在每次随访中,父母都被要求评估富含cbd的大麻治疗的有效性。根据家长报告,6例(19.35%)患者的日常生活活动无变化。治疗的主要改善如下:10例患者行为问题减少(32.2%),7例患者表达语言增加(22.5%),4例患者认知改善(12.9%),3例患者社交互动增加(9.6%),1例患者刻板印象减少(3.2%)。父母报告说,坚持服用富含cbd的大麻治疗两年以上的患者认知能力有所改善。只有一名出现轻度ASD症状的患者才能停用抗精神病药物。其他药物的使用和剂量没有变化。此外,本研究还对有关CBD治疗自闭症谱系障碍的文献进行了广泛的回顾。根据最近的研究,CBD的平均剂量为3.8±2.6 mg/kg/天。所用制剂中CBD与THC的比例为20:1。最显著的改善出现在20-70%的患者的行为问题上。结论:使用低剂量的CBD和痕量四氢大麻酚似乎有望治疗与自闭症相关的行为问题。此外,这种治疗可以有效地控制核心症状和认知功能。与其他研究相比,低剂量的富含cbd的大麻没有发现明显的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信